Uterine (Endometrial) Cancer

 

  • CR1816MK Advanced, Recurrent or Metastatic Endometrial Cancer: Lenvatinib plus Pembrolizumab 
    2nd Line:  Immunotherapy or Chemotherapy  
    Study Drug:
    Lenvatinib plus Pembrolizumab vs Physician's choice (Doxorubicin or paclitaxel)
    Main Inclusion Criteria: 
    •    Radiographic evidence of progression after 1 prior platinum-based chemotherapy; progression < 1 year eligible without further chemotherapy 
    •    Tumor biopsy specimen - MMR status. 
    Main Exclusion Criteria: 
    •    Carcinosarcoma (malignant mixed mullerian tumor), endometrial leiomyosarcoma and endometrial stromal sarcomas
     [Details]
     
  • CR1525MK Advance Solid Tumor:  Pembrolizumab, 2nd Line
    Main Inclusion criteria:
    •    Any advanced solid tumor which is Microsatellite Instability (MSI)-High (MSI-H)
    •    There is no limit to the number of prior treatment regimens
    •    Can supply tumor tissue for study analyses 

      Main Exclusion Criteria:
      
•    Active autoimmune disease that has required systemic treatment in the past 2 years
      •    Previously participated in any other pembrolizumab (MK-3475) study, or received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-Ligand 1 (anti-PD-L1), anti-PD-L2
       [Details]

  • CA209-848  Solid Tumors of High Tumor Mutational Burden (TMB-H)  Nivolumab +/- Ipilimumab
    Main Inclusion Criteria:
    •    Solid malignant tumor with TMB-H 
    •    Available tumor tissue and blood for TMB testing 
    •    Measurable disease

    Main Exclusion Criteria:
    •    Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody
     [Details]
  • CAPTUR (Canadian Profiling and Targeted Agent Utilization Trial)
    Study Drug: targeted therapies
    Main Inclusion Criteria: (screening step - non-drug specific)
    •    Tumour genomic or protein expression testing 
    •    Patients must have measurable disease
    •    ECOG performance status 0-2

    Main Exclusion Criteria:
    •    Patients who do not meet drug-specific eligibility requirements for the drug selected by the treating physician
     [Details]

 

 

Page last updated on 

We always seek feedback to make our site better.